Patient Reported Outcome Measures in Chronic Neuropathic Pain Clinical Trials - A Systematic Literature Review.

Chronic neuropathic pain domains patient reported outcome measures randomized controlled trials systematic review

Journal

The journal of pain
ISSN: 1528-8447
Titre abrégé: J Pain
Pays: United States
ID NLM: 100898657

Informations de publication

Date de publication:
01 2023
Historique:
received: 26 04 2022
revised: 22 08 2022
accepted: 01 09 2022
pubmed: 11 10 2022
medline: 27 12 2022
entrez: 10 10 2022
Statut: ppublish

Résumé

In neuropathic pain clinical trials, the patient's perspective is often insufficiently reflected focusing mainly on pain intensity. Comparability of outcome assessment is limited due to heterogenous patient reported outcome measures (PROMs). The MEDLINE, CENTRAL, and Embase databases and reference lists of published meta-analyses were searched. Randomized controlled studies assessing treatment efficacy of drugs for chronic neuropathic pain were included. PROMs were assigned to recommended IMMPACT/NeuPSIG domains: pain intensity, pain other aspects, physical functioning, emotional functioning, global improvement and satisfaction, adverse events, participant disposition. Domains and PROMs were compared regarding the publication year and methodological quality of the studies. Within the 251 included studies 200 PROMs were used with 27 being recommended by IMMPACT/NeuPSIG. The number of domains was higher in high/moderate quality studies. The (sub-) domains 'physical functioning', 'global improvement and satisfaction', and 'neuropathic pain quality' were assessed more frequently in high/moderate quality studies and those published after 2011. Recent studies and those of better quality more often used the recommended PROMs. Although neuropathic assessment via PROMs has improved, there is still a high heterogeneity. A standardized core set of outcome domains and should be defined to improve neuropathic pain treatment and to achieve better comparability of clinical trials. Perspective: This systematic literature review assesses the use of patient reported outcome measures (PROMs) in chronic neuropathic pain. The results show that there is still a high heterogeneity, highlighting the need for a standardized core set of outcome domains and PROMs to improve comparability of clinical trials and neuropathic pain treatment.

Identifiants

pubmed: 36216128
pii: S1526-5900(22)00393-5
doi: 10.1016/j.jpain.2022.09.003
pii:
doi:

Types de publication

Systematic Review Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

38-54

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Juliane Sachau (J)

Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany. Electronic address: juliane.sachau@uksh.de.

Manon Sendel (M)

Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.

Marie Péchard (M)

Inserm U987, APHP, UVSQ, Paris-Saclay University, CHU Ambroise Paré, Boulogne-Billancourt, France.

Kathrin Schnabel (K)

Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital of Muenster, Münster.

Iris Schmieg (I)

Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital of Muenster, Münster.

Terkia Medkour (T)

Inserm U987, APHP, UVSQ, Paris-Saclay University, CHU Ambroise Paré, Boulogne-Billancourt, France.

Laurent Ecochard (L)

Novartis Pharma AG, Basel, Switzerland.

Markus Woischnik (M)

Bayer AG, Berlin, Germany.

Hiltrud Liedgens (H)

Grünenthal, Germany GmbH, Aachen, Germany.

Esther Pogatzki-Zahn (E)

Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital of Muenster, Münster.

Ralf Baron (R)

Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.

Didier Bouhassira (D)

Inserm U987, APHP, UVSQ, Paris-Saclay University, CHU Ambroise Paré, Boulogne-Billancourt, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH